PCSK9 and familial hypercholesterolemia: Over the past 20 years, much has been learned about the PCSK9 pathway, stemming from the breakthrough finding in 2003 where gain of function mutations in PCSK9 were shown to be the third locus of familial hypercholesterolemia [41,42].